Literature DB >> 7743996

Cyclin D2 and Ha-Ras transformed rat embryo fibroblasts exhibit a novel deregulation of cell size control and early S phase arrest in low serum.

E Kerkhoff1, E B Ziff.   

Abstract

The D-type cyclins are growth factor-regulated delayed early functions which peak at the G1/S transition, are thought to regulate entry into S phase and have been implicated in tumorigenesis. Here, we show that cyclin D2 can co-operate with Ha-Ras to impose a novel transformed state on rat embryo fibroblasts (REF). While clonal cyclin D2/Ha-Ras REF transformants exhibit a characteristic transformed phenotype in high serum, in low serum they arrest cell proliferation and display profound morphological and cytological changes indicating loss of control of cell mass and deregulation of the G1/S transition. Notably, in low serum, despite re-establishment of actin cables and arrest of proliferation, cell mass continues to increase, creating giant cells up to 10 x normal size. Also, during low-serum culture the cells make a very gradual but progressive entry into S phase, reaching a 2.4N DNA content after 6 days. PCNA is expressed and 2N and 4N cells are largely absent, and thus the cells undergo a novel S phase arrest. While transfer to low serum induced the retinoblastoma protein to enter its dephosphorylated state, and cyclin A, cyclin B and cdc2 levels to decrease, all as normal, cyclin E, cdk4, cdk2 and the exogenous cyclin D2 persisted at high levels. These results indicate that cyclin D2 and Ha-Ras can transform cells when mitogenic signals from growth factors are provided. However, in low serum, co-operation of cyclin D2 and Ha-Ras provides only a subset of the progression signals and these are sufficient for G1-related cell mass increase and S phase entry, but are insufficient for full cell cycling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743996      PMCID: PMC398288          DOI: 10.1002/j.1460-2075.1995.tb07181.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  61 in total

1.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.

Authors:  D W Goodrich; N P Wang; Y W Qian; E Y Lee; W H Lee
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

2.  Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering.

Authors:  D J Templeton; S H Park; L Lanier; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Modulation of retinoblastoma protein activity during the cell cycle.

Authors:  S Mittnacht; P W Hinds; S F Dowdy; R A Weinberg
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1991

Review 4.  Eukaryotic DNA polymerases.

Authors:  T S Wang
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

5.  Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides.

Authors:  Q J Hu; C Bautista; G M Edwards; D Defeo-Jones; R E Jones; E Harlow
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

6.  Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B.

Authors:  J Pines; T Hunter
Journal:  Nature       Date:  1990-08-23       Impact factor: 49.962

7.  Identification of a novel gene, Vin-1, in murine leukemia virus-induced T-cell leukemias by provirus insertional mutagenesis.

Authors:  P J Tremblay; C A Kozak; P Jolicoeur
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

9.  Cyclin A is required for the onset of DNA replication in mammalian fibroblasts.

Authors:  F Girard; U Strausfeld; A Fernandez; N J Lamb
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  7 in total

1.  Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.

Authors:  M Meyyappan; H Wong; C Hull; K T Riabowol
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

2.  Gris1, a new common integration site in Graffi murine leukemia virus-induced leukemias: overexpression of a truncated cyclin D2 due to alternative splicing.

Authors:  Catherine Denicourt; Christine A Kozak; Eric Rassart
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Myc represses transcription of the growth arrest gene gas1.

Authors:  T C Lee; L Li; L Philipson; E B Ziff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition.

Authors:  Etsuo Susaki; Keiko Nakayama; Keiichi I Nakayama
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

5.  Identification of new cell size control genes in S. cerevisiae.

Authors:  Huzefa Dungrawala; Hui Hua; Jill Wright; Lesley Abraham; Thivakorn Kasemsri; Anthony McDowell; Jessica Stilwell; Brandt L Schneider
Journal:  Cell Div       Date:  2012-12-12       Impact factor: 5.130

6.  Role of interleukin-18 in modulation of oral carcinoma cell proliferation.

Authors:  Athip Nilkaeo; Suthinee Bhuvanath
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

7.  BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma.

Authors:  Xue Wang; Chunyu Wang; Guangqi Yan; Yuanyuan Kang; Ge Sun; Shengli Wang; Renlong Zou; Hongmiao Sun; Kai Zeng; Huijuan Song; Wei Liu; Ning Sun; Wensu Liu; Yue Zhao
Journal:  EBioMedicine       Date:  2020-02-27       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.